Leukemia, Myelodysplasia, Transplantation
Video
Live from ASH: Dr. David Henry shares his 'did you know' picks
News
TOPPS: Limit prophylactic platelets to select groups
Major Finding: The primary endpoint of WHO grade 2 or higher bleeding was seen in 50% with no prophylaxis (151 of 300) and 43% receiving...
News
Chemo-free combo tames 'worst of the worst' acute leukemia
Major Finding: Two-year event-free survival was 86.7% with all-trans retinoic acid (ATRA) and chemotherapy and 97% with ATRA plus arsenic trioxide...
News
FDA approves ponatinib for CML and Ph-positive ALL
News
Targeting new myeloma pathway pays off with ARRY-520
Major Finding: The overall response rate to single-agent ARRY-520 was 16% in patients with a median of 6 prior regimens and 22% when combined with...
News
Experimental quizartinib gives bridge to transplant in relapsed AML
Major Finding: Median overall survival in patients who were positive for the FLT3-ITD mutation and received a transplant was 33.3 weeks, vs.
Video
HEM-ONC CHAT: Dr. Elias Jabbour, 'Treatment a la Carte in CML'
News
Fewer Deaths with Tighter Hematocrit Target in Polycythemia Vera
Major Finding: In this study, 2.8% of patients treated to a hematocrit target of less than 45% experienced one or more events in a composite...
News
With Ponatinib, CML Resistance Is Squashed - For Now
Major Finding: In heavily pretreated patients with relapsed or refractory chronic-phase CML, ponatinib produced a major cytogenetic response in 56...
News
Induction Anthracycline Skipped in Pediatric Leukemia Regimen
Major Finding: The 5-year overall survival among children with B-cell lineage ALL treated without daunorubicin in the induction regimen was 98%,...
News
Experimental Ibrutinib Could Change Treatment of CLL
Major Finding: Ibrutinib monotherapy produced an overall response rate of 68% in previously untreated patients and 71% in patients with relapsed...